Have Immunovant, Inc. (NASDAQ:IMVT) Insiders Been Selling Their Stock?

By
Simply Wall St
Published
January 09, 2022
NasdaqGS:IMVT
Source: Shutterstock

Anyone interested in Immunovant, Inc. (NASDAQ:IMVT) should probably be aware that the Chief Medical Officer, William Macias, recently divested US$222k worth of shares in the company, at an average price of US$8.28 each. The eyebrow raising move amounted to a reduction of 12% in their holding.

View our latest analysis for Immunovant

Immunovant Insider Transactions Over The Last Year

Notably, that recent sale by William Macias is the biggest insider sale of Immunovant shares that we've seen in the last year. So we know that an insider sold shares at around the present share price of US$7.99. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. Given that the sale took place at around current prices, it makes us a little cautious but is hardly a major concern.

In the last twelve months insiders purchased 35.75k shares for US$287k. But they sold 26.81k shares for US$222k. Overall, Immunovant insiders were net buyers during the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

insider-trading-volume
NasdaqGS:IMVT Insider Trading Volume January 9th 2022

There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).

Insider Ownership of Immunovant

Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. Our data suggests Immunovant insiders own 0.2% of the company, worth about US$2.0m. I generally like to see higher levels of ownership.

So What Do The Immunovant Insider Transactions Indicate?

An insider hasn't bought Immunovant stock in the last three months, but there was some selling. On the other hand, the insider transactions over the last year are encouraging. But we'd like it if insiders owned more stock, overall. So we can't be sure that insiders are optimistic. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. For instance, we've identified 5 warning signs for Immunovant (2 don't sit too well with us) you should be aware of.

Of course Immunovant may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Discounted cash flow calculation for every stock

Simply Wall St does a detailed discounted cash flow calculation every 6 hours for every stock on the market, so if you want to find the intrinsic value of any company just search here. It’s FREE.

Make Confident Investment Decisions

Simply Wall St's Editorial Team provides unbiased, factual reporting on global stocks using in-depth fundamental analysis.
Find out more about our editorial guidelines and team.